Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03 2024 - 7:15AM
Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage
company developing transformational treatments for patients with
serious metabolic diseases marked by high unmet medical need, today
announced that management will present at the 42nd Annual J.P.
Morgan Healthcare Conference on Monday, January 8, 2024, at 09:45
a.m. P.T. in San Francisco, CA.
A live webcast of the Company presentation will be available
through the investor relations section of the Company's website
at www.akerotx.com. Following the live webcast, an archived
replay will be available on the Company's website.
About Akero TherapeuticsAkero Therapeutics is a
clinical-stage company developing transformational treatments for
patients with serious metabolic diseases marked by high unmet
medical need, including NASH/MASH, a disease without any approved
therapies. Akero's lead product candidate, EFX, is currently being
evaluated in two ongoing, 96-week Phase 2b clinical trials, the
HARMONY study in patients with pre-cirrhotic NASH/MASH (F2-F3
fibrosis), and the SYMMETRY study in patients with cirrhotic
NASH/MASH (F4 fibrosis, compensated), as well as two Phase 3
clinical trials, the SYNCHRONY Histology study in
patients with pre-cirrhotic NASH/MASH (F2-F3 fibrosis) and the
SYNCHRONY Real-World study in patients with NASH/MASH or
NAFLD/MASLD. Akero is headquartered in South San Francisco.
Visit akerotx.com and follow us
on LinkedIn and Twitter for more
information.
Investor Contact:Christina TartagliaStern
Investor Relations,
Inc.212.362.1200christina.tartaglia@sternir.com
Media Contact:Sarah
O’Connell732.456.0092soconnell@vergescientific.com
Akero Therapeutics (NASDAQ:AKRO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Akero Therapeutics (NASDAQ:AKRO)
Historical Stock Chart
From Jul 2023 to Jul 2024